Literature DB >> 32780902

Posttranslationally Acting Arginases Provide a Ribosomal Route to Non-proteinogenic Ornithine Residues in Diverse Peptide Sequences.

Silja Mordhorst1, Brandon I Morinaka2, Anna L Vagstad1, Jörn Piel1.   

Abstract

Ornithine is a component of many bioactive nonribosomal peptides but is challenging to incorporate into ribosomal products. We recently identified OspR, a cyanobacterial arginase-like enzyme that installs ornithines in the antiviral ribosomally synthesised and posttranslationally modified peptide (RiPP) landornamide A. Here we report that OspR belongs to a larger family of peptide arginases from diverse organisms and RiPP types. In E. coli, seven selected enzymes converted arginine into ornithine with little preference for the leader type. A broad range of peptide sequences was modified, including polyarginine repeats. We also generated analogues of ornithine-containing nonribosomal peptides using RiPP technology. Five pseudo-nonribosomal products with ornithines at the correct positions were obtained, including a brevicidine analogue containing ornithine and a d-amino acid installed by the peptide epimerase OspD. These results suggest new opportunities for peptide bioengineering.
© 2020 Wiley-VCH GmbH.

Entities:  

Keywords:  RiPPs; arginases; biosynthesis; enzymes; ornithine; peptides

Mesh:

Substances:

Year:  2020        PMID: 32780902     DOI: 10.1002/anie.202008990

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  2 in total

1.  Ribosomally derived lipopeptides containing distinct fatty acyl moieties.

Authors:  Florian Hubrich; Nina M Bösch; Clara Chepkirui; Brandon I Morinaka; Michael Rust; Muriel Gugger; Serina L Robinson; Anna L Vagstad; Jörn Piel
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-18       Impact factor: 11.205

Review 2.  A roadmap for metagenomic enzyme discovery.

Authors:  Serina L Robinson; Jörn Piel; Shinichi Sunagawa
Journal:  Nat Prod Rep       Date:  2021-11-17       Impact factor: 13.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.